News
EVFM
0.0096
-12.73%
-0.0014
Weekly Report: what happened at EVFM last week (1124-1128)?
Weekly Report · 3d ago
Evofem Biosciences Holds Annual Meeting, Votes on Key Proposals
TipRanks · 11/26 22:20
Weekly Report: what happened at EVFM last week (1117-1121)?
Weekly Report · 11/24 10:36
Weekly Report: what happened at EVFM last week (1110-1114)?
Weekly Report · 11/17 10:37
Evofem Biosciences Reports Q3 2025 Earnings
TipRanks · 11/14 04:28
Evofem Biosciences Q3 EPS $(0.01) Up From $(0.02) YoY, Sales $4.952M Up From $4.496M YoY
Benzinga · 11/13 23:14
Evofem Biosciences GAAP EPS of -$0.01, revenue of $4.95M
Seeking Alpha · 11/13 21:44
*Evofem Biosciences 3Q Sales $5M >EVFM
Dow Jones · 11/13 21:14
*Evofem Biosciences 3Q Loss/Shr 1c >EVFM
Dow Jones · 11/13 21:05
*Evofem Biosciences 3Q Loss $1.57M >EVFM
Dow Jones · 11/13 21:05
Press Release: Evofem Reports Financial Results -2-
Dow Jones · 11/13 21:05
Weekly Report: what happened at EVFM last week (1103-1107)?
Weekly Report · 11/10 10:34
Weekly Report: what happened at EVFM last week (1027-1031)?
Weekly Report · 11/03 10:34
Weekly Report: what happened at EVFM last week (1020-1024)?
Weekly Report · 10/27 10:38
Evofem Biosciences Ends Merger with Aditxt, Refocuses Strategy
TipRanks · 10/20 22:00
*Aditxt Agreement to Buy Evofem Was Announced in December 2023
Dow Jones · 10/20 21:26
*Evofem Biosciences Terminates Aditxt Agreement
Dow Jones · 10/20 21:24
*Evofem Biosciences: Pivoting to Focus on Regaining a National Listing for Stock and Securing Capital
Dow Jones · 10/20 21:24
*Evofem Biosciences: Stockholders Didn't Approve Aditxt Merger
Dow Jones · 10/20 21:23
Press Release: Evofem Announces Voting Results from Special Meeting of Stockholders
Dow Jones · 10/20 20:19
More
Webull provides a variety of real-time EVFM stock news. You can receive the latest news about Evofem Bioscienc through multiple platforms. This information may help you make smarter investment decisions.
About EVFM
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.